Lung Health and the Microbiome Among Adults in Botswana: the Go-hema Cohort

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age35+
SponsorDuke University

About this trial

Chronic respiratory diseases like chronic obstructive pulmonary disease (COPD) are responsible for millions of deaths each year, the majority of which occur in low- and middle-income countries (LMICs). LMICs also have high rates of abnormal lung function, including restrictive spirometric pattern (RSP), which can precede the development of chronic respiratory diseases and is associated with all-cause mortality. Additionally, LMICs in sub-Saharan Africa are home to the majority of the world's population of people with HIV (PWH). HIV increases the risk of COPD and COPD associated mortality, but the mechanisms underlying this risk are incompletely understood.

Eligibility criteria

Qualifiers

Adults 35 years of age or older

In case at a clinic in Botswana

Documented HIV status

Ability to provide informed consent

Disqualifiers

Respiratory infection in the prior 4 weeks

Active pulmonary tuberculosis

Inability to perform spirometry including eye, abdominal, or

Thoracic surgery or myocardial infarction in the prior 6 weeks

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

900 Participants
are grouped into 1 trial group

Sponsors and collaborators